2021 Vanguard Forum for Healthcare and Life Sciences Leaders.jpg

What Has Changed in The Healthcare and Life Sciences Ecosystems? What Should We Do About It?

Over the past two years, the world has changed. But what aspects of change really matter to our roles as leaders? And what should we be doing in response?

Here are some of the topics we addressed at this year's Forum:

 

  • How have business development and licensing evolved with the COVID 19 effect on science, the changing regulatory environment, and the impact of remote working?

  • What are the trends that will make a decisive difference to health care systems over the next decade?

  • What are the implications of ESG?

  • Will the importance of social impact factors be making a fundamental difference in healthcare and life sciences?

  • And what about the intensifying demands for effective leadership as well as scientific acumen -- and the new job and career expectations of millennials, and generation Z?


At this Forum, CEOs and C-Suite leaders took stock of where they are, where they need to be going, and how to get there. No PowerPoint, no speeches; rather, pragmatic, peer-to-peer dialogues, simulations and networking around the leadership topics that will make a decisive difference.

FORUM CO-CHAIRS

  • David King; Operating Partner - Healthcare, Pritzker Private Capital; Board of Directors, BinxHealth

  • Paul Hastings; Chairman, BIO; CEO, Nkarta Therapeutics

SESSION LEADERS

  • Carolyn Morgan; President, PrecisionHealth

  • Ambar BoodhooPartner, Ernst & Young

  • Kathy Ku; Chief Licensing Advisor, Wilson Sonsini

  • Cal Roberts, MD; CEO, Lighthouse Guild

  • David King; Operating Partner - Healthcare, Pritzker Private Capital; Board of Directors, BinxHealth

  • Michelle McMurry Heath; President & CEO, BIO

  • Cameron Durrant; Chairman & CEO, Humanigen

  • Stephen Brengle; Managing Director, WittKieffer

  • Ray JordanCommunications & Public Affairs Consultant, Former Global Head of Corporate Affairs: Moderna, Amgen, J&J

  • Eric Dube; President & CEO, Travere Therapeutics

  • Cheryl Pemberton-Graves; Chief Volunteer Officer, Lighthouse Guild

  • Paul Hastings; Chairman, BIO; CEO, Nkarta Therapeutics

  • Julie Gerberding; Executive Vice President, Merck

  • Nate McCutcheon; COO & EVP, Shionogi Inc.

AGENDA, NOV 17
NOON TO 5 PM ET

SESSIONS

  • Welcome and introductions

  • The new transformation agendas

  • Break

  • Are Healthcare and Life Sciences really social impact enterprises?

  • Peer discussion

  • Break

  • New value: Where will it be created, and how?

  • Small group workshop

To view session leaders and descriptions, please click here.

AGENDA, NOV 18
9 AM TO NOON ET

SESSIONS

  • Small group workshop

  • It's a people problem: The biggest challenge in our industry

  • Break

  • New agendas: Patient engagement and ESG

  • Leading for the next decade

  • Closing comments

To view session leaders and descriptions, please click here.

UNDERWRITTEN BY

Debevoise & Plimpton